Granules India Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹1,560 Cr +20.3% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
G

Granules India Ltd

Q4 FY25Pharmaceuticals & Biotechnology

Granules India Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,197Cr
+1.8% YoY
+5.2% QoQ
Net profit
₹152Cr
+16.9% YoY
+28.8% QoQ
Margin
21%
−1 pp YoY
+1 pp QoQ
Price₹858
Market cap₹20.9K Cr
P/E32.2

The short version

Oncology portfolio expected to start yielding revenues from FY '28 onwards, with a broad pipeline including first-to-launch and Para IV products. Oncology portfolio expected to start generating revenue from FY '28 onwards, with multiple filings planned quarterly.

From Granules India Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Oncology portfolio expected to start yielding revenues from FY '28 onwards, with a broad pipeline including first-to-launch and Para IV products.
  • Expansion of the Europe and Rest of World (ROW) business, focusing on finished dosages and increasing API and PFI business.
  • Increased focus on formulation segment, aiming for around 25% of revenues from API with emphasis on in-house consumption.
  • Genome Valley formulation site to play a significant role in revenue growth, especially as Gagillapur facility normalizes post-remediation.
  • Strategic shift towards high-margin finished dosage products leading to improved gross margins.
  • Granules Life Sciences capacity utilization projected to increase from about 40% in current year to over 90% next year, driving revenue growth.
  • Planned continuous R&D and new product launches to sustain medium to long-term growth.

2 more points from Granules India Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Granules India Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Granules India spent Rs. 313 crores on Granules Life Sciences (GLS) in FY '25, with additional CAPEX planned in FY '26.
  • CAPEX for FY '26 is guided at Rs. 600 crores, covering GLS expansion, oncology, and peptide investments.
  • CZRO project CAPEX is minimal in FY '25, focusing on land acquisition and pilot facilities; expansion to proceed cautiously.
  • Peptide R&D facility is being set up in Hyderabad, followed by peptide manufacturing.
  • Senn Chemicals acquisition involves ongoing CAPEX for enhancing CDMO capabilities and GLP-1 product development; the investment is over and above the Rs. 600 crore CAPEX for Granules.
  • Total CAPEX including Senn Chemicals is expected to be around Rs. 1,100 crores (Rs. 600 crores + Rs. 450 crores enterprise value for Senn).

2 more points from Granules India Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Granules India Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Granules India has a strong and diverse product portfolio with a total of 127 dossiers filed across various regions.
  • They have 85 ANDAs in the US (16 pending approval), 18 dossiers in Europe (10 pending approval), and 24 in other regions including Canada (8 pending approval).
  • In Q4 FY '25, they filed 3 US ANDAs and 6 European dossiers, including a first-to-file product from the GPI facility.
  • The oncology pipeline includes around 10 products under development with filings already initiated in US and Europe.
  • The ADHD portfolio has about 10 products in the pipeline, including day 1 launches, day 181 opportunities, and some first-to-file.

2 more points from Granules India Ltd's call on order book

Create a free account to keep reading this call

Granules India Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Granules India Ltd Q4 FY25 results — key figures

Granules India Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue1,1971,176+1.8%1,138+5.2%
Operating profit (EBITDA)252256-1.6%230+9.6%
Operating margin21%22%-1 pp20%+1 pp
Profit before tax198176+12.5%153+29.4%
Net profit (PAT)152130+16.9%118+28.8%
EPS (₹)6.275.35+17.2%4.85+29.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.6K Cr, net profit ₹182 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q4 FY25)

    Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Anuh Pharma (Q4 FY25)

    For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

  • Themis Medicare (Q4 FY25)

    71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Lincoln Pharmaceuticals (Q4 FY25)

    Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Granules India Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Granules India Ltd Q4 FY25 results?

Oncology portfolio expected to start yielding revenues from FY '28 onwards, with a broad pipeline including first-to-launch and Para IV products. Oncology portfolio expected to start generating revenue from FY '28 onwards, with multiple filings planned quarterly.

What is Granules India Ltd share price analysis?

Granules India Ltd currently shows a neutral. The stock trades at a P/E of 32.2 with a market cap of ₹20,941 Cr. Investors should review the full earnings analysis for detailed insights.

Is Granules India Ltd planning capital expenditure?

Granules India spent Rs. 313 crores on Granules Life Sciences (GLS) in FY '25, with additional CAPEX planned in FY '26.

Keep Granules India Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.